Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant
HBsAg positive patients in prevention of HBV vertical transmission. Single group patients
were enrolled to receive emtricitabine till 24 weeks after delivery.
Phase:
Phase 4
Details
Lead Sponsor:
Asian-Pacific Alliance of Liver Disease, Beijing
Collaborators:
Beijing Ditan Hospital Hebei Medical University Pharmaceutical Factory National Health and Family Planning Commission, P.R.China